Scinai ends PC111 licensing deal, shifts R&D focus to NanoAb platform
Reuters2026/09/08 13:19- Scinai Immunotherapeutics ended its PC111 option and license arrangements with PinCell, shifting R&D focus to its NanoAb platform.
- Option conditions expired Aug. 31, 2026, triggering termination; no extension agreement was reached.
- Move avoids new PC111 funding commitments, reallocating capital and management capacity toward its CDMO unit’s commercial execution.
- NanoAb priorities include two IL-17 programs; intradermal psoriasis candidate seeks about EUR 12 million in Poland grant funding.
- CDMO pipeline showed about USD 3.1 million in committed customer orders as of Aug. 16, 2026; 2026 revenue target remains about USD 5 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Storage Giant Offers Huge Bonuses Again: Micron Awards Up to 68 Months’ Bonus
Micron Technology has announced record-breaking bonuses for its employees in Taiwan, ranging from 35 to 68 months’ salary, with a minimum cash compensation of 1.7 million New Taiwan dollars. However, the Taoyuan union, representing about two-thirds of Micron’s workers in Taiwan, has refused to accept the offer, insisting that 15% of operating profits be included in the bonus distribution and maintaining the threat of a strike.
Crypto prices
More
